By InsightArea Editorial Team
Eli Lilly reported third-quarter revenue of $24.4 billion, up 39% from a year earlier, and raised its full-year sales forecast. At the same time, its updated adjusted earnings outlook was reduced after charges associated with acquired research more than offset an improvement in the underlying forecast.
The company’s October 29, 2026 release attributed revenue growth primarily to Mounjaro and Zepbound. Dollar figures are U.S. dollars. This is an investment analysis, not a comparison of treatment suitability or medical advice.
Volume and price tell different stories
Lilly reported a 53% increase in volume and a 15% decrease in realized prices in the quarter. Volume growth can lift sales even while the average realized price falls. But aggregate changes do not describe the price paid by every patient, insurer or country.
The company also said approximately $900 million in quarterly revenue reflected benefits including milestones and favorable rebate and discount estimate adjustments. These items matter when considering how much of a quarterly result might recur.
Why can earnings guidance fall when sales guidance rises?
Lilly raised its 2026 revenue guidance to $91 billion–$92 billion. It also increased the midpoint of its underlying non-GAAP EPS outlook, but said $4.57 per share of acquired in-process research and development charges more than offset that increase, producing an updated adjusted EPS range of $35–$36.
Reuters reported that the charges related primarily to recent deals. Acquired research spending can be important to long-term growth even when it weighs on current earnings; the eventual value of the acquired projects is uncertain.
Reported and adjusted earnings
Reported quarterly EPS was $7.22, while non-GAAP EPS was $7.48. Both included the acquired research charges identified by the company. Investors should read the reconciliation rather than assuming that every acquisition-related item is excluded from an adjusted figure.
Guidance is an estimate based on management’s assumptions about demand, manufacturing, competition and costs. Changes in coverage or pricing can affect both patients and the company, but financial results do not establish which medicine is appropriate for an individual.
What to watch
Follow volume and realized prices separately, the contribution from one-time items, manufacturing capacity, development spending and cash flow. An expanding market can support growth without removing competition, regulatory risk or uncertainty about future returns.
This article is educational and is not personalized investment advice.
Explore How to Do Hard Things for readers interested in tackling difficult goals.
Comments are closed.